Literature DB >> 18379370

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.

Shang-Gin Wu, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18379370     DOI： 10.1097/JTO.0b013e318169e32a

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authors:  Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

2.  Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.

Authors:  Fumihiro Shoji; Daigo Kawano; Kensaku Ito; Yosuke Morodomi; Tokujiro Yano; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

3.  T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Authors:  Chunyan Ma; Shuzhen Wei; Yong Song
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

Review 4.  Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.

Authors:  Navneet Singh; Aditya Jindal; Digambar Behera
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood.

Authors:  Shamini Selvarajah; Sophie Plante; Marsha Speevak; Andrea Vaags; Darren Hamelinck; Martin Butcher; Elizabeth McCready; Daria Grafodatskaya; Normand Blais; Danh Tran-Thanh; Xiaoduan Weng; Rami Nassabein; Wenda Greer; Ryan N Walton; Bryan Lo; Doug Demetrick; Stephanie Santos; Bekim Sadikovic; Xiao Zhang; Tong Zhang; Tara Spence; Tracy Stockley; Harriet Feilotter; Philippe Joubert
Journal:  JTO Clin Res Rep       Date:  2021-07-13

6.  Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.

Authors:  Marzena Anna Lewandowska; Wojciech Jóźwicki; Cezary Jochymski; Janusz Kowalewski
Journal:  Oncol Rep       Date:  2013-07-01       Impact factor: 3.906

7.  Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.

Authors:  Ye Jiang; Jing Zhang; Juanjuan Huang; Bo Xu; Ning Li; Lei Cao; Mingdong Zhao
Journal:  BMC Pulm Med       Date:  2018-11-20       Impact factor: 3.317
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.